Nuo Therapeutics (AURX) 10-Q2007 Q3 Quarterly report

Filed: 14 Nov 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: advisory, advocacy, AMA, amputation, anniversary, appointment, Arun, assembled, attractive, automatically, bearing, began, Benson, ber, binding, broadest, burden, cast, CellMedix, commonly, compelling, compensatory, complement, concert, correct, corroborate, David, DC, death, debilitating, decline, deficit, Deva, disability, Drohan, engineered, exceeded, expenditure, exuding, fall, FAS, feasibility, front, function, gradual, greatly, half, hardware, hinder, hire, HMA, hourly, importantly, infection, issuable, launch, local, located, longer, lost, lump, mandatory, Mark, marked, markedly, maturity, McLoughlin, mechanically, methodology, milestone, misinterpretation, Nephew, ninety, Novem, outcome, owing, packaging, penalty, perfunctory, placement, presence, publicly, pursuit, ratify, recurrence, representation, resale, rescind, rescission, sell, settled, simple, simulated, single, Smith, sought, strike, structure, suitable, sum, summary, supervision, survival, team, thirty, titledFDA, tracking, transfer, turn, ulcer, ultrasound, unacceptable, unexpired, unhindered, valid, waiver, Washington, withheld, Workgroup

Removed: accomplished, activate, addressed, agent, arrive, asserted, barrier, baseline, bleeding, carry, CBER, center, Chicago, claim, clinically, clotting, compliance, complication, concomitant, contend, count, defend, delivered, demonstrate, denied, equitable, equivalent, evaluated, expressed, extensively, forward, funding, hematology, important, laboratory, large, larger, manner, medicine, naturally, offer, permit, positioned, predicate, premature, prevalent, produce, proprietary, refined, reimbursed, rejecting, relevant, response, room, showed, small, stop, subset, substantial, substantially, tendency, unsuccessful, weighed

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AURX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350 and in connection with the annual report of Cytomedix, Inc. (the “Company”) for the nine months ended September 30, 2007, I, Andrew S. Maslan, Chief Financial Officer of the Company, hereby certify that to the best of my knowledge and belief:

1.	The Company’s Form 10-Q for the nine months ended September 30, 2007, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Company’s Form 10-Q for the nine months ended September 30, 2007, fairly presents, in all material respects, the financial condition and results of operations of the Company for said period.




/s/Andrew S. Maslan
Andrew S. Maslan Chief Financial Officer
Date: November 14, 2007

A signed original of this written statement has been provided to Cytomedix, Inc. and will be retained by Cytomedix, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.